Date: January 18, 2022
Your Name: Xiaojun Bi
Manuscript Title: Genomic profiling reveals non-small cell lung cancer with common mutations of EGFR
exon 20 and exon 21: a case report
Manuscript number (if known): TCR-21-2604-CL
•

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Xiaojun BiNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ Xiaojun BiNone	
3	Royalties or licenses	_ Xiaojun BiNone	
4	Consulting fees	Xiaojun BiNone	

5	Payment or honoraria for	_ Xiaojun BiNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events		
6	Payment for expert	_ Xiaojun BiNone	
	testimony		
7	Current for attanding	Vissius Di Nese	
7	Support for attending meetings and/or travel	_ Xiaojun BiNone	
8	Patents planned, issued or	Xiaojun BiNone	
Ũ	pending		
	P		
9	Participation on a Data	Xiaojun Bi None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ Xiaojun BiNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Xiaojun BiNone	
12	Dessint of an invest	Vienius Di Mara	
12	Receipt of equipment,	_ Xiaojun BiNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	Xiaojun BiNone	
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

_ Xiaojun Bi ___ I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: January 18, 2022				
Your Name: Pengyu Song				
Manuscript Title: Genomic profiling reveals non-small cell lung cancer with common mutations of EGFR				
exon 20 and exon 21: a case report				
Manuscript number (if known): <u>TCR-21-2604-CL</u>				
, , , ,				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Pengyu SongNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ Pengyu SongNone	
3	Royalties or licenses	_ Pengyu SongNone	
4	Consulting fees	Pengyu SongNone	

5	Payment or honoraria for lectures, presentations,	_ Pengyu SongNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_ Pengyu SongNone	
7	Support for attending meetings and/or travel	_ Pengyu SongNone	
8	Patents planned, issued or pending	Pengyu SongNone	
9	Participation on a Data Safety Monitoring Board or	Pengyu SongNone	
	Advisory Board		
10	Leadership or fiduciary role	_ Pengyu SongNone	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	Pengyu SongNone	
12	Receipt of equipment,	Pengyu SongNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Pengyu SongNone	
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

_ Pengyu Song __ I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: January 18, 2022	
Your Name: Chengye Wang	
Manuscript Title: Genomic profiling reveals non-small cell lung cancer with common mutations of EGFF	{
exon 20 and exon 21: a case report	
Manuscript number (if known): <u>TCR-21-2604-CL</u>	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Chengye WangNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ Chengye WangNone	
3	Royalties or licenses	_ Chengye WangNone	
4	Consulting fees	Chengye WangNone	

5	Payment or honoraria for	_ Chengye WangNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_ Chengye WangNone	
	testimony		
7	Support for attending meetings and/or travel	_ Chengye WangNone	
8	Patents planned, issued or	Chengye WangNone	
	pending		
0	Deutisia stiene en e Dete		
9	Participation on a Data Safety Monitoring Board or	Chengye WangNone	
	Advisory Board		
10	Leadership or fiduciary role	_ Chengye WangNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Chengye WangNone	
12	Receipt of equipment,	Chengye WangNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Chengye WangNone	
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

_ Chengye Wang ___ I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: January 18, 2022
Your Name: Xuefei Zhang
Manuscript Title: Genomic profiling reveals non-small cell lung cancer with common mutations of EGFR
exon 20 and exon 21: a case report
Manuscript number (if known): TCR-21-2604-CL
• • •

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Xuefei ZhangNone	
pro	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ Xuefei ZhangNone	
3	Royalties or licenses	_ Xuefei ZhangNone	
4	Consulting fees	Xuefei ZhangNone	

5	Payment or honoraria for	_ Xuefei ZhangNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_ Xuefei ZhangNone	
	testimony		
7	Support for attending meetings and/or travel	_ Xuefei ZhangNone	
8	Patents planned, issued or	Xuefei ZhangNone	
	pending		
0	Douticipation on a Data	Vuofoi Zhong - Nono	
9	Participation on a Data Safety Monitoring Board or	Xuefei ZhangNone	
	Advisory Board		
10	Leadership or fiduciary role	_ Xuefei ZhangNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Xuefei ZhangNone	
12			
12	Receipt of equipment, materials, drugs, medical	_ Xuefei ZhangNone	
	writing, gifts or other		
	services		
13	Other financial or non-	Xuefei ZhangNone	
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

_ Xuefei Zhang __ I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: January 18, 2022					
Your Name: Changhong Liu					
Manuscript Title: Genomic profiling reveals non-small cell lung cancer with common mutations of EGFR					
exon 20 and exon 21: a case report					
Manuscript number (if known): <u>TCR-21-2604-CL</u>					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Changhong LiuNone				
	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ Changhong LiuNone				
3	Royalties or licenses	_ Changhong LiuNone				
4	Consulting fees	Changhong LiuNone				

5	Payment or honoraria for lectures, presentations,	_ Changhong LiuNone	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_ Changhong LiuNone	
	testimony		
_			
7	Support for attending meetings and/or travel	_ Changhong LiuNone	
8	Patents planned, issued or	Changhong LiuNone	
	pending		
0	Douticipation on a Data	Changhang Live Name	
9	Participation on a Data Safety Monitoring Board or	Changhong LiuNone	
	Advisory Board		
10	Leadership or fiduciary role	_ Changhong LiuNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Changhong LiuNone	
12	Dessint of any inmant	Changhang Liu Nana	
12	Receipt of equipment, materials, drugs, medical	_ Changhong LiuNone	
	writing, gifts or other		
	services		
13	Other financial or non-	Changhong LiuNone	
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

_ Changhong Liu ___ I certify that I have answered every question and have not altered the wording of any of the questions on this